Pyr-T

Use and effects

In his 1997 book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin reported neither the dose range nor the duration of the drug. However, individual experiments employed 25 to 50mg orally and 70mg smoked. Pyr-T produced effects including malaise, feeling sick, unpleasantness, salivation, muscle and joint pains, dizziness, feeling high, and uncomfortableness. Hallucinogenic effects, for instance visuals, were either absent or minor.

Interactions

Pharmacology

Pharmacodynamics

Pyr-T has been found to show affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A and 5-HT2C receptors. Its affinities () for these receptors were 30nM for the serotonin 5-HT1A receptor, 110nM for the 5-HT2A receptor, and 750nM for the serotonin 5-HT2B receptor. The affinities of pyr-T for the serotonin 5-HT2A and 5-HT2B receptors were similar to but slightly lower than those of dimethyltryptamine (DMT), whereas its affinity for the serotonin 5-HT1A receptor was 5.7-fold higher than that of DMT and was intermediate between those of DMT and 5-MeO-DMT. The serotonin 5-HT1A to 5-HT2A receptor affinity ratios in the study were about 0.27 for pyr-T, 0.5 for 5-MeO-DMT, 1.4 for bufotenin, 2.3 for DMT, and 32 for psilocin.

Pyr-T has been found to produce behavioral changes in animal tests. It was described as being as potent as diethyltryptamine (DET) in rodents, cats, and primates, but that it also had a poor margin of activity relative to toxicity and was unlikely to be tested in humans. It has been found to produce hypolocomotion in rodents. Conversely, pyr-T (3mg/kg) failed to acutely produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.

Chemistry

Pyr-T is a pyrrolidinylethylindole and a substituted tryptamine in which the amine moiety has been replaced with a pyrrolidine ring. It can be thought of as a cyclized derivative of diethyltryptamine (DET) in which the N,N-ethyl groups have been connected to form the pyrrolidine ring present in pyr-T.

Synthesis

The chemical synthesis of pyr-T has been described.

Analogues

Derivatives of pyr-T include 4-HO-pyr-T, 5-MeO-pyr-T, and 4-F-5-MeO-pyr-T. Analogues of pyr-T include pip-tryptamine, 10,11-secoergoline (α,N-Pip-T), MPMI, and SN-22, among others.

History

Pyr-T was first characterized by Mitzal by 1962. Animal toxicity testing was later performed by Hunt and Brimblecombe by 1967. The effects of pyr-T in humans were described by Alexander Shulgin in his book TiHKAL in 1997.

References

References

1. (1975). "Hallucinogenic Agents". Wright-Scientechnica.
2. (1997). "TiHKAL, The Continuation". Transform Press.
3. (2014). "Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays". Journal of Cheminformatics.
4. (2018). "Current Topics in Behavioral Neurosciences".
5. (March 1990). "Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes". Neuropharmacology.
6. (January 2020). "Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice". Biomol Ther (Seoul).
7. (1997). "TiHKAL, The Continuation". Transform Press.
8. (1962). "N/A". Dissertationes Pharm.
9. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry.